Pfizer, Icagen ink development pact
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Pfizer |
Icagen |
Development pact |
Icagen stands to pocket up to $359 million in milestones for successful programs that target three sodium ion channels as a mechanism for controlling pain. |
|
Sonic |
Bioscientia |
$256.4M buyout |
Bioscientia has been acquired by Sonic Healthcare, which valued the company at €190 million. |
|
Nektar Therapeutics |
Bayer Healthcare |
$225M licensing deal |
Nektar Therapeutics is getting $50 million up front in a $175 million licensing deal for the successful development of a new therapy for severe pneumonia. |
|
Archemix |
Ophthotech |
Licensing deal |
Archemix granted Ophthotech worldwide rights to all ophthalmic uses of Archemix's proprietary aptamers targeting the C5 component of the complement cascade. |